WO2006094209A3 - N-benzimidazolylalkyl-substituted amide sirtuin modulators - Google Patents

N-benzimidazolylalkyl-substituted amide sirtuin modulators Download PDF

Info

Publication number
WO2006094209A3
WO2006094209A3 PCT/US2006/007655 US2006007655W WO2006094209A3 WO 2006094209 A3 WO2006094209 A3 WO 2006094209A3 US 2006007655 W US2006007655 W US 2006007655W WO 2006094209 A3 WO2006094209 A3 WO 2006094209A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
sirtuin
disorders
benzimidazolylalkyl
substituted amide
Prior art date
Application number
PCT/US2006/007655
Other languages
French (fr)
Other versions
WO2006094209A2 (en
Inventor
Michael Milburn
Jill Milne
Karl D Normington
Original Assignee
Sirtris Pharmaceuticals Inc
Michael Milburn
Jill Milne
Karl D Normington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc, Michael Milburn, Jill Milne, Karl D Normington filed Critical Sirtris Pharmaceuticals Inc
Publication of WO2006094209A2 publication Critical patent/WO2006094209A2/en
Publication of WO2006094209A3 publication Critical patent/WO2006094209A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are novel sirtuin-modulating compounds of formula ( Ia ) and methods of use thereof . The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
PCT/US2006/007655 2005-03-03 2006-03-03 N-benzimidazolylalkyl-substituted amide sirtuin modulators WO2006094209A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65895105P 2005-03-03 2005-03-03
US60/658,951 2005-03-03
US71034805P 2005-08-22 2005-08-22
US60/710,348 2005-08-22

Publications (2)

Publication Number Publication Date
WO2006094209A2 WO2006094209A2 (en) 2006-09-08
WO2006094209A3 true WO2006094209A3 (en) 2007-01-11

Family

ID=36941868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/007655 WO2006094209A2 (en) 2005-03-03 2006-03-03 N-benzimidazolylalkyl-substituted amide sirtuin modulators

Country Status (1)

Country Link
WO (1) WO2006094209A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2416610C2 (en) 2004-12-30 2011-04-20 Астекс Терапьютикс Лимитед Pharmaceutical compounds
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
EP2049119A2 (en) 2006-06-29 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea
DE102007037579B4 (en) 2007-08-09 2012-05-16 Emc Microcollections Gmbh New benzimidazol-2-yl-alkylamines and their use as microbicidal agents
CA2723135A1 (en) 2008-05-01 2009-11-05 Sirtris Pharmaceuticals, Inc. Quenolines and related analogs as sirtuin modulators
WO2010003048A1 (en) * 2008-07-03 2010-01-07 Sirtris Pharmaceuticals, Inc. Benzimidazoles and related analogs as sirtuin modulators
MX2011003239A (en) 2008-09-26 2011-04-28 Merck Sharp & Dohme Novel cyclic benzimidazole derivatives useful anti-diabetic agents.
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5535931B2 (en) 2008-10-27 2014-07-02 武田薬品工業株式会社 Bicyclic compound
EP2352374B1 (en) 2008-10-29 2014-09-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102369014A (en) 2008-12-08 2012-03-07 西北大学 Method of modulating HSF-1
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011116176A1 (en) * 2010-03-17 2011-09-22 Sirtris Pharmaceuticals Inc. 3-substitued imidazo (4, 5-b) pyridines and analogs as sirtuin modulators
EA025380B1 (en) 2011-02-25 2016-12-30 Мерк Шарп Энд Домэ Корп. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2013074948A1 (en) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
KR20150036245A (en) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 Antidiabetic tricyclic compounds
CN104718004A (en) 2012-08-22 2015-06-17 默沙东公司 Novel azabenzimidazole hexahydrofuro[3,2-b]furan derivatives
US9527839B2 (en) 2012-08-22 2016-12-27 Merck Sharp & Dohme Corp. Benzimidazole tetrahydropyran derivatives
ES2755087T3 (en) 2012-08-22 2020-04-21 Merck Sharp & Dohme Benzimidazole hexahydrofide [3,2-b] furan derivatives useful as activators of AMP-activated protein kinase
US9868733B2 (en) 2012-08-22 2018-01-16 Merck Sharp & Dohme Corp. Azabenzimidazole tetrahydrofuran derivatives
US9382243B2 (en) 2012-08-22 2016-07-05 Merck Sharp & Dohme Corp. Azabenzimidazole tetrahydropyran derivatives
WO2014031441A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydrofuran derivatives
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10519115B2 (en) 2013-11-15 2019-12-31 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
WO2017052360A1 (en) * 2015-09-21 2017-03-30 Universiti Sains Malaysia Compounds for use as anti-cancer agents
KR20240038149A (en) 2017-04-26 2024-03-22 바실리어 파마슈티카 인터내셔널 리미티드 Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099131A2 (en) * 2003-04-30 2004-11-18 Pharmacia Corporation Compounds having a fused, bicyclic moiety for binding to the minor groove of dsdna
WO2005002672A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response
WO2005037272A1 (en) * 2003-10-22 2005-04-28 Arpida A/S Benzimidazole derivatives and use thereof as peptide deformylase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099131A2 (en) * 2003-04-30 2004-11-18 Pharmacia Corporation Compounds having a fused, bicyclic moiety for binding to the minor groove of dsdna
WO2005002672A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response
WO2005002555A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
WO2005037272A1 (en) * 2003-10-22 2005-04-28 Arpida A/S Benzimidazole derivatives and use thereof as peptide deformylase inhibitors

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ARIENTI K. L., ET AL.: "Checkpoint Kinase Inhibitors: SAR and Radioprotective Properties of a Series of 2-Arylbenzimidazoles", JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, no. 6, 2005, pages 1873 - 1885, XP002400069 *
BALBONI G, ET AL.: "Evaluation of the Dmt-Tic Pharmacophore: Conversion of a Potent delta-Opioid Receptor Antagonist into a Potent delta-Agonist and Ligands with Mixed Properties", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 3, 2002, pages 713 - 720, XP002400064 *
GÖKER H., ET AL.: "Synthesis of Some New 2-substituted-phenyl-1H-benzimidazole-5-carbonitriles and Their Potent Activity Against Candida Species", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 10, 2002, pages 2589 - 2596, XP002400067 *
HUFF J. R., ET AL.: "Convenient and Regioselective synthesis of Substituted 2,3,4,5-Tetrahydro-1H-[1,4]diazepino[1,7-a]benzimidazoles", JOURNAL OF ORGANIC CHEMISTRY, vol. 47, no. 3, 1982, pages 582 - 585, XP002400065 *
RANGARAJAN M., ET AL.: "2''-Substituted 5-Phenylterbenzimidazoles as Topomerase I Poisons", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 8, 2000, pages 1371 - 1382, XP002400063 *
RENAU T. E., ET AL.: "Peptidomimetics of Efflux Pump Inhibitors Potentiate the Activity of Levofloxacin in Pseudomonas aeruginosa", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, 2002, pages 763 - 766, XP002400062 *
SHIN J.M., ET AL.: "Chemistry of Covalent Inhibition of the Gastric (H+,K+)-ATPase by Proton Pump Inhibitors", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 126, no. 25, 2004, pages 7800 - 7811, XP002400068 *
VEDULA M.S., ET AL.: "New styryl sulfones as anticancer agents", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, 2003, pages 811 - 824, XP002400070 *
WU Z., ET AL.: ""One-pot" nitro reduction-cyclisation solid phase route to benzimidazoles", TETRAHEDRON LETTERS, vol. 41, 2000, pages 9871 - 9874, XP002400066 *
YEH C-M., ET AL.: "Rapid Parallel Synthesis of benzimidazoles", SYNLETT, no. 6, 1999, pages 810 - 812, XP002400071 *

Also Published As

Publication number Publication date
WO2006094209A2 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
WO2006094209A3 (en) N-benzimidazolylalkyl-substituted amide sirtuin modulators
WO2006094210A3 (en) Tetrahydroquinoxalinone sirtuin modulators
WO2008156869A3 (en) Sirtuin modulating thiazolopyridine compounds
WO2009134973A8 (en) Quinolines and related analogs as sirtuin modulators
MY149316A (en) Sirtuin modulating imidazohiazole compounds
MX2010004965A (en) Amide derivatives as sirtuin modulators.
WO2007019344A8 (en) Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds
WO2010037127A8 (en) Chromenone analogs as sirtuin modulators
WO2006094246A3 (en) N-arylmethyl benzamide sirtuin modulators
MX2011006555A (en) Thiazolopyridine sirtuin modulating compounds.
WO2006078941A3 (en) Novel sirtuin activating compounds and methods of use thereof
MX2010012961A (en) Imidazopyridine and related analogs as sirtuin modulators.
MX2011006084A (en) Isoindolinone and related analogs as sirtuin modulators.
MX2011006475A (en) Phthalazinone and related analogs as sirtuin modulators.
WO2006105440A3 (en) Nicotinamide riboside and analogues thereof
WO2009061453A8 (en) Solubilized thiazolopyridines
IN2012DN03799A (en)
WO2006094237A3 (en) Acridine and quinoline dervatives as sirtuin modulators
MX2011009213A (en) 8-substituted quinolines and related analogs as sirtuin modulators.
WO2007102861A3 (en) Modulators of cdc2-like kinases (clks) and methods of use thereof
WO2008100376A3 (en) Truncation variants of sirt1 and methods of use thereof
EA201170137A1 (en) BENZIMIDAZLES AND RELATED ANALOGUES AS SIRTUIN MODULATORS
WO2014186313A8 (en) Substituted bridged urea analogs as sirtuin modulators
WO2007127474A3 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2009085226A3 (en) Inhibitors of cdc2-like kinases (clks) and methods of use thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06736901

Country of ref document: EP

Kind code of ref document: A2